JP2017504632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504632A5 JP2017504632A5 JP2016549045A JP2016549045A JP2017504632A5 JP 2017504632 A5 JP2017504632 A5 JP 2017504632A5 JP 2016549045 A JP2016549045 A JP 2016549045A JP 2016549045 A JP2016549045 A JP 2016549045A JP 2017504632 A5 JP2017504632 A5 JP 2017504632A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- effective amount
- crystalline form
- liver fibrosis
- jnk1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 206010016654 Fibrosis Diseases 0.000 claims 18
- 210000004185 Liver Anatomy 0.000 claims 18
- 108010087301 Mitogen-Activated Protein Kinase 8 Proteins 0.000 claims 18
- 108010087313 Mitogen-Activated Protein Kinase 9 Proteins 0.000 claims 18
- 230000004761 fibrosis Effects 0.000 claims 18
- 206010012601 Diabetes mellitus Diseases 0.000 claims 9
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims 9
- 206010025135 Lupus erythematosus Diseases 0.000 claims 9
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 9
- 206010039710 Scleroderma Diseases 0.000 claims 9
- 102000004965 antibodies Human genes 0.000 claims 9
- 108090001123 antibodies Proteins 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 9
- 201000009594 systemic scleroderma Diseases 0.000 claims 9
- 208000001083 Kidney Disease Diseases 0.000 claims 8
- 206010029149 Nephropathy Diseases 0.000 claims 8
- 206010029151 Nephropathy Diseases 0.000 claims 8
- 230000001684 chronic Effects 0.000 claims 8
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 1
- QBBRJRLJWXRSHQ-CKYFFXLPSA-N C[C@H](CC[C@H](C1)Nc2nc(NC(C)(C)C)ncc2C(N)=O)[C@@H]1O Chemical compound C[C@H](CC[C@H](C1)Nc2nc(NC(C)(C)C)ncc2C(N)=O)[C@@H]1O QBBRJRLJWXRSHQ-CKYFFXLPSA-N 0.000 description 1
Claims (36)
- 有効量の請求項1記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項1記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項1記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項2記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項2記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項2記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項3記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項3記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項3記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項4記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項4記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項4記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項5記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項5記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項5記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項6記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項6記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項6記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項7記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項7記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項7記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項8記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項8記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項8記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
- 有効量の請求項9記載の結晶形態を含む、JNK1又はJNK2キナーゼを発現している細胞において該JNK1又はJNK2キナーゼを阻害するための医薬組成物。
- 有効量の請求項9記載の結晶形態を含む、間質性肺線維症、全身性強皮症、強皮症、慢性移植腎症、抗体関連型拒絶反応、又は狼瘡を治療するための医薬組成物。
- 有効量の請求項9記載の結晶形態を含む、肝線維症疾患、糖尿病、又は、肝線維症疾患につながる代謝症候群を治療するための医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461933636P | 2014-01-30 | 2014-01-30 | |
US61/933,636 | 2014-01-30 | ||
US201462025161P | 2014-07-16 | 2014-07-16 | |
US62/025,161 | 2014-07-16 | ||
PCT/US2015/013412 WO2015116755A2 (en) | 2014-01-30 | 2015-01-29 | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019071044A Division JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの固体形態、その組成物、及びその使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017504632A JP2017504632A (ja) | 2017-02-09 |
JP2017504632A5 true JP2017504632A5 (ja) | 2018-04-19 |
Family
ID=53678405
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016549045A Pending JP2017504632A (ja) | 2014-01-30 | 2015-01-29 | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの固体形態、その組成物、及びその使用方法 |
JP2019071044A Active JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの固体形態、その組成物、及びその使用方法 |
JP2020127493A Active JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | 2-(tert-ブチルアミノ)-4-((1R,3R,4R)-3-ヒドロキシ-4-メチルシクロヘキシルアミノ)-ピリミジン-5-カルボキサミドの固体形態、その組成物、及びその使用方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019071044A Active JP6742466B2 (ja) | 2014-01-30 | 2019-04-03 | 2−(tert−ブチルアミノ)−4−((1R,3R,4R)−3−ヒドロキシ−4−メチルシクロヘキシルアミノ)−ピリミジン−5−カルボキサミドの固体形態、その組成物、及びその使用方法 |
JP2020127493A Active JP7317768B2 (ja) | 2014-01-30 | 2020-07-28 | 2-(tert-ブチルアミノ)-4-((1R,3R,4R)-3-ヒドロキシ-4-メチルシクロヘキシルアミノ)-ピリミジン-5-カルボキサミドの固体形態、その組成物、及びその使用方法 |
Country Status (31)
Country | Link |
---|---|
US (6) | US9365524B2 (ja) |
EP (2) | EP3738954A1 (ja) |
JP (3) | JP2017504632A (ja) |
KR (2) | KR102505677B1 (ja) |
CN (3) | CN106163523A (ja) |
AU (2) | AU2015211036B2 (ja) |
BR (2) | BR122020003206B1 (ja) |
CA (1) | CA2938187C (ja) |
CL (1) | CL2016001927A1 (ja) |
CR (1) | CR20160346A (ja) |
CY (1) | CY1123267T1 (ja) |
DK (1) | DK3099302T3 (ja) |
EA (2) | EA036964B1 (ja) |
ES (1) | ES2811834T3 (ja) |
HR (1) | HRP20201244T1 (ja) |
HU (1) | HUE051266T2 (ja) |
IL (2) | IL246931B (ja) |
LT (1) | LT3099302T (ja) |
MX (3) | MX2020003173A (ja) |
MY (1) | MY180020A (ja) |
NZ (3) | NZ715903A (ja) |
PE (1) | PE20161437A1 (ja) |
PH (1) | PH12016501472B1 (ja) |
PL (1) | PL3099302T3 (ja) |
PT (1) | PT3099302T (ja) |
RS (1) | RS60715B1 (ja) |
SA (1) | SA516371578B1 (ja) |
SG (1) | SG11201606054SA (ja) |
SI (1) | SI3099302T1 (ja) |
TW (1) | TWI631108B (ja) |
WO (1) | WO2015116755A2 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI548621B (zh) | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
NZ715903A (en) * | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
EA033530B1 (ru) * | 2014-12-16 | 2019-10-31 | Signal Pharm Llc | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида |
JP6903577B2 (ja) * | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ,エルエルシー | 皮膚におけるc−Jun N末端キナーゼの阻害の測定方法 |
WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
CN111934089B (zh) | 2019-05-13 | 2021-10-26 | 华为技术有限公司 | 天线装置及移动终端 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH549339A (de) | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
US5852028A (en) * | 1995-12-18 | 1998-12-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5811428A (en) * | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
EP1054004B1 (en) | 1997-12-15 | 2008-07-16 | Astellas Pharma Inc. | Novel pyrimidine-5-carboxamide derivatives |
DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
EP1184376B1 (en) | 1999-06-09 | 2005-02-02 | Yamanouchi Pharmaceutical Co. Ltd. | Novel heterocyclic carboxamide derivatives |
WO2000076980A1 (fr) | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
JPWO2003082855A1 (ja) | 2002-03-28 | 2005-08-04 | 協和醗酵工業株式会社 | 抗炎症剤 |
MXPA04012855A (es) * | 2002-06-28 | 2005-04-19 | Yamanouchi Pharma Co Ltd | Derivado de diaminopirimidincarboxiamida. |
ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
AU2003293409A1 (en) * | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
AU2003289330A1 (en) | 2002-12-13 | 2004-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
WO2004067516A1 (en) | 2003-01-30 | 2004-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta |
MY147449A (en) | 2003-08-15 | 2012-12-14 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
AU2004275733A1 (en) | 2003-09-24 | 2005-04-07 | Wyeth Holdings Corporation | 5-arylpyrimidines as anticancer agents |
WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
WO2006014482A1 (en) | 2004-07-08 | 2006-02-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of pkc-theta |
WO2006027378A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Roflumilast and syk inhibitor combination and methods of use thereof |
CA2579007A1 (en) | 2004-09-10 | 2006-03-16 | Altana Pharma Ag | Ciclesonide and syk inhibitor combination and methods of use thereof |
CN101027288B (zh) | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | 抑制hiv的5-取代嘧啶 |
JP2006124387A (ja) | 2004-09-30 | 2006-05-18 | Taisho Pharmaceut Co Ltd | 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法 |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
WO2006099231A1 (en) | 2005-03-10 | 2006-09-21 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
BRPI0715418A2 (pt) | 2006-07-21 | 2013-03-26 | Novartis Ag | compostos de 2,4-di(arilaminio)-pirimidina-5-carboxamida como inibidores de cinases jak |
US20080139531A1 (en) | 2006-12-04 | 2008-06-12 | Alcon Manufacturing Ltd. | Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair |
CN101678215B (zh) | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的磺酰胺衍生物 |
RU2009143753A (ru) | 2007-04-27 | 2011-06-10 | Астразенека Аб (Se) | Производные n'-(фенил)-n-(морфолин-4-ил-пиридин-2-ил)-пиримидин-2, 4-идиамина в качестве ингибиторов ернв4 киназы для лечения пролиферативных состояний |
AU2008277446A1 (en) | 2007-07-16 | 2009-01-22 | Astrazeneca Ab | Pyrimidine derivatives 934 |
CA2693594A1 (en) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
KR20170051521A (ko) | 2008-04-16 | 2017-05-11 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
KR101623997B1 (ko) * | 2008-04-16 | 2016-05-24 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
UY31929A (es) | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
US20110159019A1 (en) | 2008-09-01 | 2011-06-30 | Akira Tanaka | 2,4-diaminopyrimidine compound |
EP2331507A2 (en) | 2008-09-18 | 2011-06-15 | Astellas Pharma Inc. | Heterocyclic carboxamide compounds |
WO2010038081A2 (en) | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
BRPI0919885A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
EP2375899B1 (en) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Piperidine-containing compounds and use thereof in the treatment of diabetes |
BRPI1006162A2 (pt) | 2009-01-13 | 2019-09-24 | Glaxo Group Ltd | "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto". |
EP2389373B1 (en) | 2009-01-21 | 2017-05-17 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
EP3009428B1 (en) * | 2009-05-08 | 2018-02-21 | Astellas Pharma Inc. | Diamino heterocyclic carboxamide compound |
EP2440548A1 (en) | 2009-06-10 | 2012-04-18 | Abbott Laboratories | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
JP2012197231A (ja) | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ttk阻害作用を有するピリジンおよびピリミジン誘導体 |
WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
EP2507227B1 (en) | 2009-12-01 | 2014-10-08 | Rigel Pharmaceuticals, Inc. | Tetrazolones as protein kinase c inhibitors and uses thereof |
CA2801781C (en) | 2010-07-21 | 2018-02-27 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US8580805B2 (en) * | 2010-08-31 | 2013-11-12 | Hubert Maehr | Pyrimidine carboxamide derivatives |
EP2621489A1 (en) | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
WO2012044936A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide |
TWI548621B (zh) * | 2011-04-22 | 2016-09-11 | 標誌製藥公司 | 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法 |
JP6113828B2 (ja) * | 2012-04-04 | 2017-04-12 | ライジェル ファーマシューティカルズ, インコーポレイテッド | プロテインキナーゼc阻害剤およびその使用 |
WO2014089112A1 (en) * | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
JP6421170B2 (ja) * | 2013-03-14 | 2018-11-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | プロテインキナーゼc阻害剤およびその使用 |
CN104262328B (zh) * | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
MX2016007898A (es) * | 2013-12-20 | 2016-10-07 | Signal Pharm Llc | Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos. |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
EA033530B1 (ru) * | 2014-12-16 | 2019-10-31 | Signal Pharm Llc | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида |
WO2016123291A1 (en) * | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
-
2014
- 2014-09-03 NZ NZ715903A patent/NZ715903A/en unknown
-
2015
- 2015-01-29 NZ NZ761068A patent/NZ761068A/en unknown
- 2015-01-29 BR BR122020003206-5A patent/BR122020003206B1/pt active IP Right Grant
- 2015-01-29 SI SI201531322T patent/SI3099302T1/sl unknown
- 2015-01-29 NZ NZ722412A patent/NZ722412A/en unknown
- 2015-01-29 ES ES15743503T patent/ES2811834T3/es active Active
- 2015-01-29 JP JP2016549045A patent/JP2017504632A/ja active Pending
- 2015-01-29 CN CN201580016658.4A patent/CN106163523A/zh active Pending
- 2015-01-29 EP EP20178344.6A patent/EP3738954A1/en active Pending
- 2015-01-29 EA EA201792281A patent/EA036964B1/ru not_active IP Right Cessation
- 2015-01-29 MX MX2020003173A patent/MX2020003173A/es unknown
- 2015-01-29 CR CR20160346A patent/CR20160346A/es unknown
- 2015-01-29 EA EA201691544A patent/EA031671B1/ru not_active IP Right Cessation
- 2015-01-29 US US14/608,314 patent/US9365524B2/en active Active
- 2015-01-29 TW TW104103137A patent/TWI631108B/zh active
- 2015-01-29 PL PL15743503T patent/PL3099302T3/pl unknown
- 2015-01-29 CN CN202110386057.XA patent/CN113717109A/zh active Pending
- 2015-01-29 EP EP15743503.3A patent/EP3099302B1/en active Active
- 2015-01-29 RS RS20200970A patent/RS60715B1/sr unknown
- 2015-01-29 BR BR112016017776A patent/BR112016017776A8/pt not_active Application Discontinuation
- 2015-01-29 PE PE2016001300A patent/PE20161437A1/es not_active Application Discontinuation
- 2015-01-29 CN CN202110386098.9A patent/CN113717110A/zh active Pending
- 2015-01-29 KR KR1020167023497A patent/KR102505677B1/ko active IP Right Grant
- 2015-01-29 PT PT157435033T patent/PT3099302T/pt unknown
- 2015-01-29 LT LTEP15743503.3T patent/LT3099302T/lt unknown
- 2015-01-29 MY MYPI2016702761A patent/MY180020A/en unknown
- 2015-01-29 SG SG11201606054SA patent/SG11201606054SA/en unknown
- 2015-01-29 WO PCT/US2015/013412 patent/WO2015116755A2/en active Application Filing
- 2015-01-29 MX MX2016009989A patent/MX2016009989A/es active IP Right Grant
- 2015-01-29 KR KR1020227013115A patent/KR20220051440A/ko not_active Application Discontinuation
- 2015-01-29 DK DK15743503.3T patent/DK3099302T3/da active
- 2015-01-29 CA CA2938187A patent/CA2938187C/en active Active
- 2015-01-29 HU HUE15743503A patent/HUE051266T2/hu unknown
- 2015-01-29 AU AU2015211036A patent/AU2015211036B2/en active Active
-
2016
- 2016-05-12 US US15/152,653 patent/US9814713B2/en active Active
- 2016-07-25 IL IL246931A patent/IL246931B/en active IP Right Grant
- 2016-07-26 PH PH12016501472A patent/PH12016501472B1/en unknown
- 2016-07-28 SA SA516371578A patent/SA516371578B1/ar unknown
- 2016-07-29 MX MX2019005715A patent/MX2019005715A/es unknown
- 2016-07-29 CL CL2016001927A patent/CL2016001927A1/es unknown
-
2017
- 2017-10-09 US US15/727,659 patent/US10226461B2/en active Active
-
2019
- 2019-02-04 US US16/266,793 patent/US10517873B2/en active Active
- 2019-04-03 JP JP2019071044A patent/JP6742466B2/ja active Active
- 2019-11-11 US US16/679,592 patent/US11241430B2/en active Active
-
2020
- 2020-03-26 AU AU2020202146A patent/AU2020202146B2/en active Active
- 2020-06-11 IL IL275305A patent/IL275305B/en unknown
- 2020-07-28 JP JP2020127493A patent/JP7317768B2/ja active Active
- 2020-08-07 HR HRP20201244TT patent/HRP20201244T1/hr unknown
- 2020-08-12 CY CY20201100757T patent/CY1123267T1/el unknown
-
2021
- 2021-12-27 US US17/562,933 patent/US20220378785A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017504632A5 (ja) | ||
HRP20201244T1 (hr) | Kristalni oblici 2-(tert-butilamino)-4-((1r,3r,4r)-3-hidroksi-4-metilcikloheksilamino)-pirimidin-5-karboksamida | |
JP2018024682A5 (ja) | ||
JP2016531087A5 (ja) | ||
MX2015013303A (es) | Compuestos heterociclicos utiles para el tratamiento de una enfermedad. | |
NZ746950A (en) | Heterocyclic gpr119 agonist compounds | |
JP2015127293A5 (ja) | ||
GEP20186841B (en) | Stabilized crystal of tipiracil hydrochloride, and crystallization method for same | |
WO2012121876A3 (en) | Azeotrope and azeotrope-like compositions useful for the production of haloolefins | |
WO2016068453A8 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
WO2016016774A8 (en) | Crystalline forms of canagliflozin | |
PL3921383T3 (pl) | Materiały zmiennofazowe (pcms) z przejściami ciało stałe w ciało stałe | |
SI3408260T1 (sl) | Kristalinična (2S,4R)-5-(5'-kloro-2-fluoro-(1,1'-bifenil)-4-il)-2- (etoksimetil)-4-(3-hidroksiizoksazol-5-karboksamido)-2-metilpentanojska kislina in uporaba le-te | |
WO2013088384A3 (en) | Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof | |
RU2017106058A (ru) | Кристаллическая форма азолбензольного производного | |
EP3019182A4 (en) | COMPOSITION COMPRISING A PURIFIED EXTRACT ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM CONTAINING AN ABUNDANT QUANTITY OF ACTIVE PRINCIPLE OR COMPOUNDS ISOLATED THEREOF AS AN ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY AND USE THEREOF | |
PL3731815T3 (pl) | Kompozycja ketaminy w postaci suchego proszku do zastosowania w leczeniu depresji przez podawanie dopłucne | |
AR119477A2 (es) | Formas sólidas amorfas de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida y dichas formas cristalinas para uso en el tratamiento de una enfermedad | |
Carman | Performance Measures | |
Blaeß | New bioactive glasses with improved sintering behavior | |
JP2015187067A5 (ja) | ||
IL249496A0 (en) | Improved process for the preparation of 4-(1-(4-(perfluoroethoxy)phenyl)-h4,2,1-1-triazol-3-yl)benzoyl azide | |
Kujundžić | Stella Fatović-Ferenčić, Jasenka Ferber Bogdan, Maja Jakševac Mikša; Ljekarnički dom: Od privatnog vlasništva do staleškog doma. | |
Бат-Ирээдүй | Acta Mongolica | |
Strauch | BaTe: bulk modulus: New Data and Updates for several IIa-VI Compounds (Structural Properties, Thermal and Thermodynamic Properties, and Lattice Properties) |